Published in Br J Addict on November 01, 1989
Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers | NCT01638377
Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics | NCT03220776
Zonisamide Outpatient Study | NCT03376139
Oxytocin Treatment for Alcohol Use Disorders (OT-ETOH-4) | NCT03636555
Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med (2014) 3.17
Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res (2010) 2.70
Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacology (2008) 2.28
Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol (2010) 1.93
Contingency management for alcohol use reduction: a pilot study using a transdermal alcohol sensor. Drug Alcohol Depend (2011) 1.87
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry (2008) 1.80
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry (2011) 1.69
Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res (2012) 1.66
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) (2004) 1.66
Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry (2011) 1.63
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry (2015) 1.62
Decreased prefrontal cortical dopamine transmission in alcoholism. Am J Psychiatry (2014) 1.48
Identifying neurobiological phenotypes associated with alcohol use disorder severity. Neuropsychopharmacology (2011) 1.41
Tips for GP trainees working in general medicine. Br J Gen Pract (2011) 1.38
Predictors of detection of alcohol use episodes using a transdermal alcohol sensor. Exp Clin Psychopharmacol (2014) 1.38
Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction (2011) 1.29
A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) (2011) 1.27
A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res (2008) 1.23
Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients. Transl Psychiatry (2013) 1.21
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry (2010) 1.21
Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry (2011) 1.17
Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol (2008) 1.17
Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking. Alcohol Clin Exp Res (2006) 1.14
Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity. Alcohol Clin Exp Res (2012) 1.12
Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl) (2008) 1.11
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol (2007) 1.10
Systematic cultural adaptation of cognitive-behavioral therapy to reduce alcohol use among HIV-infected outpatients in western Kenya. AIDS Behav (2010) 1.10
Cerebral white matter recovery in abstinent alcoholics--a multimodality magnetic resonance study. Brain (2010) 1.09
Another perspective on management of withdrawal. Can Fam Physician (1997) 1.08
Glutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changes. Drug Alcohol Depend (2012) 1.08
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res (2011) 1.08
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology (2011) 1.08
Alcohol-use disorders in the critically ill patient. Chest (2010) 1.07
Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addict Biol (2012) 1.05
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res (2012) 1.05
Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl) (2011) 1.05
Neural and behavioral mechanisms of impulsive choice in alcohol use disorder. Alcohol Clin Exp Res (2011) 1.04
Rare copy number deletions predict individual variation in intelligence. PLoS One (2011) 1.04
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology (2012) 1.03
A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend (2013) 1.03
Sleep architecture, cocaine and visual learning. Addiction (2008) 1.03
Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol (2013) 1.02
Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res (2008) 1.01
Clinical profile of patients with nascent alcohol related seizures. Ann Indian Acad Neurol (2013) 0.99
Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res (2008) 0.98
Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin Exp Res (2008) 0.98
Cognitive-behavioral therapy for insomnia in alcohol dependent patients: a randomized controlled pilot trial. Behav Res Ther (2011) 0.98
Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol (2009) 0.97
Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol (2009) 0.97
Effects of chronic alcohol dependence and chronic cigarette smoking on cerebral perfusion: a preliminary magnetic resonance study. Alcohol Clin Exp Res (2006) 0.96
Diagnosis and management of acute alcohol withdrawal. CMAJ (1999) 0.96
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res (2012) 0.95
An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics. Psychopharmacology (Berl) (2011) 0.95
Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res (2011) 0.94
Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry (2012) 0.94
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res (2009) 0.94
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addict Behav (2013) 0.94
Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology (2009) 0.94
Severity of alcoholism in Indian males: Correlation with age of onset and family history of alcoholism. Indian J Psychiatry (2010) 0.93
The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol (2010) 0.93
Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des (2010) 0.93
The impact of chronic cigarette smoking on recovery from cortical gray matter perfusion deficits in alcohol dependence: longitudinal arterial spin labeling MRI. Alcohol Clin Exp Res (2009) 0.93
Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) (2009) 0.92
Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction (2008) 0.92
Brain-derived neurotrophic factor genotype is associated with brain gray and white matter tissue volumes recovery in abstinent alcohol-dependent individuals. Genes Brain Behav (2012) 0.92
Using the AUDIT-PC to predict alcohol withdrawal in hospitalized patients. J Gen Intern Med (2014) 0.92
Test-retest variability of [¹¹C]raclopride-binding potential in nontreatment-seeking alcoholics. Synapse (2010) 0.92
Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry (2011) 0.91
Physiological and subjective responding to alcohol cue exposure in alcoholics and control subjects: evidence for appetitive responding. J Neural Transm (Vienna) (2006) 0.91
Examining perceptions of a smartphone-based intervention system for alcohol use disorders. Telemed J E Health (2014) 0.91
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology (2016) 0.90
Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol (2014) 0.90
A human alcohol self-administration paradigm to model individual differences in impaired control over alcohol use. Exp Clin Psychopharmacol (2013) 0.90
An acute psychosocial stressor does not potentiate alcohol cue reactivity in non-treatment-seeking alcoholics. Alcohol Clin Exp Res (2010) 0.90
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. Alcohol Clin Exp Res (2010) 0.90
A validation study of the alcohol dependence scale. J Stud Alcohol Drugs (2009) 0.89
Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. Alcohol Clin Exp Res (2013) 0.88
Predicting treatment seekers' readiness to change their drinking behavior in the COMBINE Study. Alcohol Clin Exp Res (2009) 0.88
Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study. Alcohol Clin Exp Res (2016) 0.87
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) (2009) 0.87
Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology (2009) 0.87
Characteristics of first-time alcohol treatment seekers: the COMBINE Study. J Stud Alcohol Drugs (2008) 0.87
Prevalence and correlates of withdrawal-related insomnia among adults with alcohol dependence: results from a national survey. Am J Addict (2010) 0.86
A qualitative study of anticipated barriers and facilitators to the implementation of nurse-delivered alcohol screening, brief intervention, and referral to treatment for hospitalized patients in a Veterans Affairs medical center. Addict Sci Clin Pract (2012) 0.85
The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse (2009) 0.85
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT. Alcohol Clin Exp Res (2014) 0.85
Drinking less and drinking smarter: direct and indirect protective strategies in young adults. Psychol Addict Behav (2012) 0.85
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl) (2014) 0.85
Validation of a nine-dimensional measure of drinking motives for use in clinical applications: the desired effects of drinking scale. Addict Behav (2011) 0.84
Differential brain response to alcohol cue distractors across stages of alcohol dependence. Biol Psychol (2012) 0.84
The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse (2008) 0.84
Structural brain differences in alcohol-dependent individuals with and without comorbid substance dependence. Drug Alcohol Depend (2014) 0.84
Neurometabolite concentration and clinical features of chronic alcohol use: a proton magnetic resonance spectroscopy study. Psychiatry Res (2012) 0.84
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav (2009) 0.83
Clinical relevance of nalmefene versus placebo in alcohol treatment: Reduction in mortality risk. J Psychopharmacol (2015) 0.83
Behavioral arousal in response to stress and drug cue in alcohol and cocaine addicted individuals versus healthy controls. Hum Psychopharmacol (2010) 0.83
Rare copy number deletions predict individual variation in human brain metabolite concentrations in individuals with alcohol use disorders. Biol Psychiatry (2011) 0.83
Evaluation of an alcohol withdrawal protocol and a preprinted order set at a tertiary care hospital. Can J Hosp Pharm (2011) 0.83
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. Alcohol Alcohol (2014) 0.82
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. Eur Neuropsychopharmacol (2015) 0.82
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
Clinical pharmacology and therapeutics of benzodiazepines. Can Med Assoc J (1978) 2.40
Nicotine metabolism defect reduces smoking. Nature (1998) 2.17
Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol (1996) 2.09
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther (1997) 2.06
Treatment of acetaminophen poisoning. Can Med Assoc J (1981) 2.05
An evaluation of the deterrent impact of Ontario's 12-hour licence suspension law. Accid Anal Prev (1988) 2.03
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) Arch Gen Psychiatry (1999) 1.94
Binding of drugs to serum albumin (first of two parts). N Engl J Med (1976) 1.85
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol (2000) 1.82
Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med (1993) 1.79
Inter- and intrasubject variation in diazepam free fraction. Clin Pharmacol Ther (1979) 1.76
RESERVE CARBOHYDRATES IN ORCHARD GRASS CLIPPED PERIODICALLY. Plant Physiol (1950) 1.75
Alcohol intoxication and withdrawal. N Engl J Med (1976) 1.74
Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci (1971) 1.67
The ambiguity of adverse drug reactions. Eur J Clin Pharmacol (1977) 1.64
Determination of gestational cocaine exposure by hair analysis. JAMA (1989) 1.63
Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med (1970) 1.59
Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther (1970) 1.58
Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol (1981) 1.56
Thromboangiitis obliterans: an old disease in need of a new look. Int J Cardiol (2000) 1.49
Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med (1976) 1.49
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther (1998) 1.44
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther (1996) 1.41
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
Assessing the outcomes of coronary artery bypass graft surgery: how many risk factors are enough? Steering Committee of the Cardiac Care Network of Ontario. J Am Coll Cardiol (1997) 1.39
Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol (1983) 1.38
Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia (2001) 1.38
An application of computers to curriculum review and planning. J Med Educ (1986) 1.38
Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol (1977) 1.33
Pneumothorax in polysubstance-abusing marijuana and tobacco smokers: three cases. J Subst Abuse (1993) 1.32
Measurement issues in postpartum depression part 1: anxiety as a feature of postpartum depression. Arch Womens Ment Health (2003) 1.30
Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. J Stud Alcohol (1977) 1.28
Variations in drug free fraction during alcohol withdrawal. Br J Clin Pharmacol (1983) 1.28
Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med (1986) 1.27
Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther (1983) 1.26
Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos (2001) 1.25
Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther (1995) 1.22
Drug kinetics and alcohol ingestion. Clin Pharmacokinet (1979) 1.22
Drug therapy: Drugs to decrease alcohol consumption. N Engl J Med (1981) 1.18
Long-term codeine use is associated with depressive symptoms. J Clin Psychopharmacol (1999) 1.18
CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther (1993) 1.16
Cloning and overexpression of glycosyltransferases that generate the lipopolysaccharide core of Rhizobium leguminosarum. J Biol Chem (1998) 1.16
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther (1983) 1.14
Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther (1981) 1.13
Influence of age and previous use of diazepam dosage required for endoscopy. Can Med Assoc J (1978) 1.09
Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation (1999) 1.08
Influence of intravenous injection rate on protein binding and vascular activity of diazoxide. Ann N Y Acad Sci (1973) 1.08
Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. J Clin Pharmacol (1976) 1.07
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol (2001) 1.06
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos (2001) 1.06
Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet (1997) 1.05
Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol (1997) 1.05
Pharmacogenetics and ethnoracial differences in smoking. JAMA (1998) 1.05
Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther (1993) 1.04
Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol (1994) 1.04
Age- and gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol (1979) 1.04
Characteristics of dependent and nondependent regular users of codeine. J Clin Psychopharmacol (1999) 1.03
Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol (1996) 1.03
Eating disorders and alcohol abuse in women. Br J Addict (1992) 1.03
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics (1998) 1.03
Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. Clin Pharmacol Ther (1981) 1.02
Complications of saphenous vein harvesting following coronary artery bypass surgery. J Cardiovasc Surg (Torino) (1990) 1.01
Update on tamper-resistant drug formulations. Drug Alcohol Depend (2013) 1.01
Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin Pharmacol Ther (1979) 1.00
Acute and chronic drug abuse emergencies in Metropolitan Toronto. Int J Addict (1981) 1.00
Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol (1982) 1.00
Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther (1997) 0.99
Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol (1988) 0.99
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun (2002) 0.99
Management of the alcohol withdrawal syndrome. Annu Rev Med (1991) 0.99
Diurnal variations in plasma diazepam concentrations associated with reciprocal changes in free fraction. Br J Clin Pharmacol (1980) 0.98
Protein binding and vascular activity of diazoxide. N Engl J Med (1969) 0.98
Liver granulomas and allopurinol. Br Med J (1978) 0.98
Furosemide-induced adverse reactions in cirrhosis of the liver. Clin Pharmacol Ther (1979) 0.98
Endogenous opioids are involved in the genetically determined high preference for ethanol consumption. Alcohol Clin Exp Res (1991) 0.98
Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol (1982) 0.97
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther (2001) 0.97
Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol (1980) 0.97
Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: reversal by increasing synaptic dopamine. J Pharmacol Exp Ther (1995) 0.96
Mood changes during pregnancy and the postpartum period: development of a biopsychosocial model. Acta Psychiatr Scand (2004) 0.96
Absolute bioavailability of moxifloxacin. Clin Ther (1999) 0.96
Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther (2006) 0.96
An improved HPLC method for analysis of methamphetamine and its metabolites in plasma. Eur J Drug Metab Pharmacokinet (1998) 0.96
Tissue factor localization in non-human primate cerebral tissue. Thromb Haemost (1992) 0.96